Distinguished in Bursectomy

Takaki Yoshikawa

Tokyo, JP 
Distinguished in Bursectomy
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Takaki Yoshikawa practices in Tokyo, Japan. Yoshikawa is rated as a Distinguished expert by MediFind in Bursectomy. Their top areas of expertise are Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Gastrectomy, and Splenectomy.

Their clinical research consists of co-authoring 433 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Bursectomy.

Locations

Tokyo, Japan
Other Locations
Chuo, Japan
Yokohama, Japan
Chuo, Japan
Kyoto, Japan
Tsukiji, Japan
Tsukiji, 1040045, Japan
Kashiwa, 2778577, Japan
Osaka, Japan
Japan
Kanagawa, Japan
Minato, Japan
Miemachi, Japan
Takatsuki, Japan
Musashimurayama, Japan
Saitama, Japan
Tokorozawa, Japan
Asahimachi, 5458585, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3

433 Total Publications

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yoshikawa's expertise for a condition
ConditionClose
View All 45 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile